ReviewDiabetes, obesity & metabolism2011
Novel insight into glucagon receptor action: lessons from knockout and transgenic mouse models.
Review in Diabetes, obesity & metabolism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 49 citations in OpenAlex.
- Cardiac neurons expressing a glucagon-like receptor mediate cardiac arrhythmia induced by high-fat diet ineLife · 2026Article
- Discovery of antibodies targeting multipass transmembrane proteins using a suspension cell-based evolutionary approach.Cell reports methods · 2023Article
- Pro-α-cell-derived β-cells contribute to β-cell neogenesis induced by antagonistic glucagon receptor antibody in type 2 diabetic mice.iScience · 2022Article
- Role of Glucagon and Its Receptor in the Pathogenesis of Diabetes.Frontiers in endocrinology · 2022Review
- Delineating the activation mechanism and conformational landscape of a class B G protein-coupled receptor glucagon receptor.Computational and structural biotechnology journal · 2022Article
- A glucagon analogue decreases body weight in mice via signalling in the liver.Scientific reports · 2021Article
- Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.Molecular metabolism · 2021Article
- Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure.JACC. Basic to translational science · 2019Article
- Design principles of the paradoxical feedback between pancreatic alpha and beta cells.Scientific reports · 2018Article
- Glucagon like receptor 1/ glucagon dual agonist acutely enhanced hepatic lipid clearance and suppressed de novo lipogenesis in mice.PloS one · 2017Article
- Mild hyperglycemia triggered islet function recovery in streptozotocin-induced insulin-deficient diabetic rats.Journal of diabetes investigation · 2017Article
- Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist.eLife · 2016Article
- Glucagon receptor antagonism induces increased cholesterol absorption.Journal of lipid research · 2015Article
- Alpha-, Delta- and PP-cells: Are They the Architectural Cornerstones of Islet Structure and Co-ordination?The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2015Review
- Glucagon is essential for alpha cell transdifferentiation and beta cell neogenesis.Development (Cambridge, England) · 2015Article
- Glucagon stimulates hepatic FGF21 secretion through a PKA- and EPAC-dependent posttranscriptional mechanism.PloS one · 2014Article
- Current insights and new perspectives on the roles of hyperglucagonemia in non-insulin-dependent type 2 diabetes.Current hypertension reports · 2013Review
- Oxyntomodulin increases intrinsic heart rate through the glucagon receptor.Physiological reports · 2013Article
- A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.Diabetologia · 2013Article
- Major facilitator superfamily domain-containing protein 2a (MFSD2A) has roles in body growth, motor function, and lipid metabolism.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Using knockout and transgenic technology, genetically modified animal models allowed us to understand the role of glucagon signalling in metabolism. Mice with a global deletion of the glucagon receptor gene (Gcgr) were designed using gene targeting. The phenotype of Gcgr(-/-) mouse provided important clues about the role of Gcgr in foetal growth, pancreatic development and glucose and lipid homeostasis. The lack of Gcgr activation was associated with: (i) hypoglycaemic pregnancies, poor foetal growth and increased foetal-neonatal demise; (ii) altered cytoarchitecture of pancreatic islets; (iii) altered glucose, lipid and hormonal milieu; (iv) reduced gastric emptying; (v) altered body composition and protection from diet-induced obesity; (vi) altered energy state; (vii) impaired hepatocyte survival; (viii) altered metabolic response to prolonged fasting and exercise and (ix) prevented development of diabetes in insulin-deficient mice. In contrast, mice overexpressing the Gcgr on pancreatic β-cells displayed an increase insulin secretion, pancreatic insulin content and β-cell mass, and partially protected against hyperglycaemia and impaired glucose tolerance when fed a high-fat diet. These findings suggest that glucagon signalling plays a significant role in the regulation of glucose and lipid homeostasis. Treatment options designed to block Gcgr activation may have negative implications in the treatment of diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.